Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, Gorfinkel I, Shu D, White L, Lasko B, Dzongowski P, Papp K, Alexander M, Boivin G, Fries L. Langley JM, et al. Among authors: ward bj. Vaccine. 2011 Feb 24;29(10):1921-8. doi: 10.1016/j.vaccine.2010.12.100. Epub 2011 Jan 8. Vaccine. 2011. PMID: 21219987 Clinical Trial.
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, Embree J, McGeer A, Zickler P, Moltz KH, Martz R, Meyer I, McNeil S, Langley JM, Martins E, Heyward WL, Martin JT. Halperin SA, et al. Vaccine. 2012 Mar 28;30(15):2556-63. doi: 10.1016/j.vaccine.2012.01.087. Epub 2012 Feb 9. Vaccine. 2012. PMID: 22326642 Clinical Trial.
Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.
Langley JM, Scheifele DW, Quach C, Vanderkooi OG, Ward B, McNeil S, Dobson S, Kellner JD, Kuhn S, Kollman T, MacKinnon-Cameron D, Smith B, Li Y, Halperin SA. Langley JM, et al. Vaccine. 2012 May 14;30(23):3389-94. doi: 10.1016/j.vaccine.2012.03.046. Epub 2012 Mar 30. Vaccine. 2012. PMID: 22469860 Clinical Trial.
Population immunity to measles in Canada using Canadian Health Measures survey data - A Canadian Immunization Research Network (CIRN) study.
Osman S, Crowcroft N, McLachlan E, Hatchette T, Perez-Iratxeta C, Joh E, Wright J, Halperin SA, Deeks S, Wilson S, Buchan S, Ward B, Gubbay J, Brisson M, Serhir B, Severini A, Bolotin S. Osman S, et al. Vaccine. 2022 May 20;40(23):3228-3235. doi: 10.1016/j.vaccine.2022.04.011. Epub 2022 Apr 28. Vaccine. 2022. PMID: 35491342 Free PMC article.
Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children.
Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Langley JM, Dobson S, Li Y, Law B, Halperin SA; Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Rapid Trials Investigators. Scheifele DW, et al. Among authors: ward bj. Pediatr Infect Dis J. 2011 May;30(5):402-7. doi: 10.1097/INF.0b013e3182068f33. Pediatr Infect Dis J. 2011. PMID: 21178654
285 results